PMID- 29578118
OWN - NLM
STAT- MEDLINE
DCOM- 20180904
LR  - 20220316
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 131
IP  - 7
DP  - 2018 Apr 5
TI  - Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with 
      Diabetes Mellitus and Complex Coronary Artery Disease during Elective 
      Percutaneous Coronary Intervention.
PG  - 764-769
LID - 10.4103/0366-6999.228251 [doi]
AB  - BACKGROUND: Despite its limitations, unfractionated heparin (UFH) has been the 
      standard anticoagulant used during percutaneous coronary intervention (PCI). This 
      study compared the safety of low-dose UFH with sequential enoxaparin with that of 
      UFH in patients with diabetes mellitus (DM) and complex coronary artery disease 
      receiving elective PCI. METHODS: In this retrospective study, 514 consecutive 
      patients with atherosclerotic cardiovascular diseases and type 2 DM were admitted 
      to the hospital and received selective PCI, from January 2013 to December 2015. 
      All patients with PCI received low-dose UFH with enoxaparin (intraductal 50 U/kg 
      UFH and 0.75 mg/kg enoxaparin, n = 254; UFH-Enox group) or UFH only (intraductal 
      100 U/kg UFH, n = 260; UFH group). The study endpoints were major adverse cardiac 
      events (MACEs), namely death, myocardial infarction (MI), stroke, target-vessel 
      immediate revascularization (TVR), and thrombolysis in MI (TIMI) major bleeding, 
      within 30 days and 1 year after PCI. Any catheter thrombosis during the procedure 
      was recorded. RESULTS: Only one patient had an intraductal thrombus in the UFH 
      group. At the 30-day follow-up, no MACE occurred in any group; seven and five 
      cases of recurrent angina and/or rehospitalization were reported in the UFH-Enox 
      and UFH groups, respectively; there was no significant difference between the two 
      groups (chi(2) = 0.11, P = 0.77). There was no TIMI major bleeding in the groups. 
      With respect to the 1-year endpoint, two cases of recurrent MI and two of TVRs 
      were reported in the UFH-Enox group, whereas in the UFH group, one case of 
      recurrent MI and three of TVRs were reported; no significant difference existed 
      between the two groups (chi(2) = 0, P = 0.99). There were 30 and 25 recurrent 
      angina and/or rehospitalizations in the UFH-Enox and UFH groups, respectively; 
      there was no significant difference between the two groups (chi(2) = 0.37, P = 
      0.57). CONCLUSION: In elective PCI, low-dose UFH with sequential enoxaparin has 
      similar effects and safety to the UFH-only method.
FAU - Huang, Ji
AU  - Huang J
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing 100029, China.
FAU - Li, Nan
AU  - Li N
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing 100029, China.
FAU - Li, Zhao
AU  - Li Z
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing 100029, China.
FAU - Hou, Xue-Jian
AU  - Hou XJ
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing 100029, China.
FAU - Li, Zhi-Zhong
AU  - Li ZZ
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, 
      Beijing 100029, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/therapeutic use
MH  - Coronary Artery Disease/*drug therapy/*surgery
MH  - Diabetes Mellitus/*drug therapy/*surgery
MH  - Enoxaparin/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods
MH  - Retrospective Studies
PMC - PMC5887733
OTO - NOTNLM
OT  - Complex Coronary Artery Disease
OT  - Elective Percutaneous Coronary Intervention
OT  - Enoxaparin
OT  - Unfractionated Heparin
COIS- There are no conflicts of interest
EDAT- 2018/03/27 06:00
MHDA- 2018/09/05 06:00
PMCR- 2018/04/05
CRDT- 2018/03/27 06:00
PHST- 2018/03/27 06:00 [entrez]
PHST- 2018/03/27 06:00 [pubmed]
PHST- 2018/09/05 06:00 [medline]
PHST- 2018/04/05 00:00 [pmc-release]
AID - ChinMedJ_2018_131_7_764_228251 [pii]
AID - CMJ-131-764 [pii]
AID - 10.4103/0366-6999.228251 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2018 Apr 5;131(7):764-769. doi: 10.4103/0366-6999.228251.